Nicorette Lozenges

Description

1. Product Overview

Nicorette Lozenges are a solid-dose nicotine replacement therapy (NRT) product containing nicotine polacrilex, designed for oromucosal absorption to alleviate withdrawal symptoms in smoking cessation protocols. Their primary industrial use is as a reference-listed drug (RLD) or generic equivalent for pharmaceutical contract manufacturing organizations (CMOs) and public health supply chains. The key value proposition is predictable, non-prescription nicotine delivery with proven bioavailability, enabling scalable population-level cessation programs. Strategically, they are critical for employers, insurers, and government health systems seeking to reduce long-term smoking-attributable healthcare expenditures.

2. Key Specifications & Technical Characteristics

• Active Pharmaceutical Ingredient (API): Nicotine polacrilex (ion-exchange resin complex)

• Excipients: Mannitol, povidone, sodium carbonate, potassium bicarbonate, acesulfame potassium, magnesium stearate, flavor agents

• Purity & Grade: USP/Ph.Eur. compliant; nicotine content 2mg or 4mg per lozenge (±3% assay tolerance)

• Physical Characteristics: Off-white to light brown, round biconvex tablet; mean diameter 9.5mm; dissolution >80% in 30 min (pH 5.5 buffer)

• Packaging Options: Industrial HDPE bottles (100, 250 count) or bulk blister packs (10 lozenges x 10 strips) with child-resistant seal

• Shelf Life: 24 months when stored at 15–25°C in original, unopened packaging

3. Core Industrial Applications

• Primary industries: Pharmaceutical manufacturing (NRT generics), workplace wellness suppliers, public healthcare tender distributors

• Operational use cases: Assembly-line repackaging into consumer SKUs; integration into employer-sponsored quit kits; bulk procurement for national smoking cessation campaigns

• Performance advantage over alternatives: Unlike nicotine patches (variable transdermal absorption) or gum (chewing-dependent release), lozenges offer swallow-safe, spit-free, consistent oromucosal uptake with less confounding variables in manufacturing validation

• Cost/efficiency benefit: Lower packaging line complexity vs. gum; no hydration requirements; longer ambient storage stability than transdermal systems, reducing supply chain cold-chain costs

4. Competitive Advantages

• Quality consistency: Monograph-compliant with full Certificate of Analysis (CoA) per batch; USP dissolution testing passed at 24 months

• Supply reliability: Dual-sourced API (EU and Asia) with 98% on-time-in-full (OTIF) performance over 18 rolling months

• Logistics capability: Global forward-stocking hubs (Rotterdam, Singapore, Chicago) enabling 5-day delivery to major industrial zones

• Price competitiveness: Tiered pricing down to $0.11/lozenge at 20MT volumes, beating branded reference product by 40–45%

• Sustainability: 100% plastic-neutral blister packaging; carbon-offset sea freight option available

• Technical support: Full regulatory dossiers (SMF, DMF) and stability data provided under confidential disclosure agreement

5. Commercial & Supply Information

• Minimum Order Quantity (MOQ): BULK 20MT (≈ 4.5 million lozenges at 4mg strength)

• Loading capacity: 20MT per standard 20-foot dry container (palletized, 12 pallets, each 1.66MT net)